TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05933395: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Sponsor: Dartmouth-Hitchcock Medical Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 135 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05933395 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05933395 Rescue Dossier →